Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cellectis SA

Current price
2.78 USD +0.06 USD (+2.21%)
Last closed 2.82 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 268 880 320 USD
Yield for 12 month +46.32 %
21.11.2021 - 28.11.2021

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8, rue de la Croix Jarry, Paris, France, 75013

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.13 USD

P/E ratio

Dividend Yield

Current Year

+755 000 USD

Last Year

+19 171 000 USD

Current Quarter

+283 000 USD

Last Quarter

+283 000 USD

Current Year

-18 469 000 USD

Last Year

+17 399 000 USD

Current Quarter

-5 060 000 USD

Last Quarter

+116 000 USD

Key Figures CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -86 747 000 USD
Operating Margin TTM -1461.26 %
PE Ratio
Return On Assets TTM -20.32 %
PEG Ratio
Return On Equity TTM -110.94 %
Wall Street Target Price 7.13 USD
Revenue TTM 9 193 000 USD
Book Value 1.18 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -88.5 %
Dividend Yield
Gross Profit TTM 23 952 000 USD
Earnings per share -1.92 USD
Diluted Eps TTM -1.92 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CLLS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 12.7962
Price Sales TTM 8.2872
Enterprise Value EBITDA -3.7821
Price Book MRQ 2.5332

Financials CLLS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLLS

For 52 weeks

0.96 USD 3.77 USD
50 Day MA 2.74 USD
Shares Short Prior Month 656 112
200 Day MA 2.47 USD
Short Ratio 6.39
Shares Short 509 869
Short Percent 4.09 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics